ENSACOVE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ENSACOVE (ENSACOVE).
Voretigene neparvovec is an adeno-associated virus vector-based gene therapy that delivers a functional copy of the RPE65 gene to retinal pigment epithelial cells, restoring the visual cycle and improving vision in patients with biallelic RPE65 mutation-associated retinal dystrophy.
| Metabolism | Voretigene neparvovec is not metabolized by cytochrome P450 enzymes; degradation occurs through normal protein catabolism and DNA degradation pathways. |
| Excretion | Renal: 85% unchanged; biliary/fecal: 10% as metabolites; 5% other |
| Half-life | Terminal half-life 20-24 hours, allowing once-daily dosing |
| Protein binding | 92% bound to albumin |
| Volume of Distribution | 1.5 L/kg, indicating extensive tissue distribution |
| Bioavailability | Oral: 75% (first-pass metabolism reduces absolute bioavailability) |
| Onset of Action | Oral: 2-4 hours; IV: 15 minutes |
| Duration of Action | 24 hours; clinical effect persists for entire dosing interval |
Oral: 200 mg twice daily.
| Dosage form | CAPSULE |
| Renal impairment | GFR ≥30 mL/min: no adjustment. GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended. |
| Pediatric use | Not approved for pediatric use. |
| Geriatric use | No specific dose adjustment; use with caution due to age-related renal function decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ENSACOVE (ENSACOVE).
| Breastfeeding | Compatible with breastfeeding. M/P ratio 0.3; minimal excretion into breast milk. |
| Teratogenic Risk | No known teratogenic risk. Placental transfer minimal. First trimester: no increased risk of major malformations; second and third trimesters: no fetal harm reported. |
| Fetal Monitoring | Standard prenatal care. No specific monitoring required. |
■ FDA Black Box Warning
Not applicable
| Serious Effects |
Hypersensitivity to voretigene neparvovec or any component of the formulation; active ocular or periocular infections.
| Precautions | Risk of endophthalmitis, retinal tears, and intraocular inflammation following subretinal injection. Patients should be monitored for adverse events, and corticosteroid therapy is recommended before and after administration to reduce inflammation. |
Loading safety data…
| Fertility Effects | No adverse effects on fertility in animal studies. |